Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496256 · ClinicalTrials.gov registry record · NA
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
A NA study of Prostate Cancer, sponsored by Palette Life Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 5
- Study locations
NCT06496256: Recruiting NA study of Prostate Cancer, sponsored by Palette Life Sciences.
NCT06496256 is a NA study of Prostate Cancer that is actively recruiting participants, run by Palette Life Sciences. The registered enrollment target is 84 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06496256, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Palette Life Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 5
- Study locations
Study Summary
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.
Primary Outcome
Investigational subjects only: Achievement of a ≥ 25% change in reduction in the volume of rectum receiving 90% of the prescription dose in 70% of the subjects.
Conditions Studied
Interventions
- DEVICE Barrigel
- DEVICE Transrectal Ultrasound
Study Locations (5)
Texas
- Urology Austin - Austin
- Houston Metro Urology - Houston
Massachusetts
- Dana Farber Cancer Institute - Boston
New Jersey
- Summit Health - Clifton
Victoria
- GenesisCare Ringwood - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06496256 shows while recruiting
NCT06496256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Barrigel is the first listed.
NCT06496256 lists 5 locations in 4 states (Texas, Massachusetts, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06496256 about?
NCT06496256 is a clinical study titled "Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial". Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.
What is the current status of trial NCT06496256?
This trial is currently recruiting. It is a NA study. The enrollment target is 84 participants. The study started on 2024-10-31. Estimated completion is 2027-12-31.
What conditions does trial NCT06496256 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06496256?
The interventions under investigation include: Barrigel (DEVICE), Transrectal Ultrasound (DEVICE).
Who is sponsoring clinical trial NCT06496256?
This trial is sponsored by Palette Life Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496256 being conducted?
This trial has 5 study locations across Massachusetts, New Jersey, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06496256's enrollment target sits among peer trials
84 365th of 735 higher than 370 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI